Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm

FVRR : 10.52 (-2.05%)
CXW : 20.57 (-0.24%)
HALO : 68.41 (-1.67%)
3 Cash-Producing Stocks with Exciting Potential

3 Cash-Producing Stocks with Exciting Potential

FOUR : 48.61 (-1.44%)
PTEN : 10.56 (+8.09%)
HALO : 68.41 (-1.67%)
2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore

2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore

S : 14.46 (+0.98%)
VSH : 26.91 (+2.20%)
HALO : 68.41 (-1.67%)
1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off

1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off

OLPX : 2.04 (unch)
REZI : 40.28 (+0.78%)
HALO : 68.41 (-1.67%)
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

SAN DIEGO , April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into...

HALO : 68.41 (-1.67%)
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

HALO : 68.41 (-1.67%)
Halozyme Appoints David Ramsay as Interim Chief Financial Officer

SAN DIEGO , March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer...

HALO : 68.41 (-1.67%)
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression ‑free survival and overall survival versus standard of care regimens

HALO : 68.41 (-1.67%)
Halozyme to Participate in Upcoming Investor Conferences

SAN DIEGO , Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present...

HALO : 68.41 (-1.67%)
2 Reasons to Like HALO (and 1 Not So Much)

2 Reasons to Like HALO (and 1 Not So Much)

HALO : 68.41 (-1.67%)

Barchart Exclusives

2 Warren Buffett Dividend Stocks to Scoop Up in April
Warren Buffett is known for favoring durable businesses with strong cash flows, the kind that can sustain and grow dividends over time. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.